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Dementia ascertainment using existing
data in UK longitudinal and cohort studies:
a systematic review of methodology
Ruth A. Sibbett1,2*, Tom C. Russ1,2,4,5, Ian J. Deary1,2,3 and John M. Starr1,2
Abstract
Background: Studies investigating the risk factors for or causation of dementia must consider subjects prior to disease
onset. To overcome the limitations of prospective studies and self-reported recall of information, the use of existing data
is key. This review provides a narrative account of dementia ascertainment methods using sources of existing data.
Methods: The literature search was performed using: MEDLINE, EMBASE, PsychInfo and Web of Science. Included articles
reported a UK-based study of dementia in which cases were ascertained using existing data. Existing data included that
which was routinely collected and that which was collected for previous research. After removing duplicates, abstracts
were screened and the remaining articles were included for full-text review. A quality tool was used to evaluate the
description of the ascertainment methodology.
Results: Of the 3545 abstracts screened, 360 articles were selected for full-text review. 47 articles were included for final
consideration. Data sources for ascertainment included: death records, national datasets, research databases and
hospital records among others. 36 articles used existing data alone for ascertainment, of which 27 used only a single
data source. The most frequently used source was a research database. Quality scores ranged from 7/16 to 16/16.
Quality scores were better for articles with dementia ascertainment as an outcome. Some papers performed validation
studies of dementia ascertainment and most indicated that observed rates of dementia were lower than expected.
Conclusions: We identified a lack of consistency in dementia ascertainment methodology using existing data. With no
data source identified as a “gold-standard”, we suggest the use of multiple sources. Where possible, studies should
access records with evidence to confirm the diagnosis. Studies should also calculate the dementia ascertainment rate
for the population being studied to enable a comparison with an expected rate.
Keywords: Dementia, Research design and methodology
Background
As the global population ages and dementia rates increase,
further research is required in order to reduce the impact
on the individual and on society [1, 2] Key aspects of
current dementia research include causation, risk factors,
early detection, and prevention. In order to investigate
such factors robustly – and avoid reverse causality – stud-
ies need to consider subjects prior to disease onset.
Whether such studies concentrate on the entire life course
or on a limited period prior to dementia onset, completing
data collection prospectively can be time-consuming and
costly. Recruiting those who already have a diagnosis in
order to consider life-course risk and protective factors is
limited by the potential inaccuracy or incompleteness of
information recalled by participants and carers.
In order to overcome such limitations, the use of previ-
ously collected data is key. The value of existing data sets is
demonstrated by the launch of The Farr Institute of Health
Informatics Research in the UK, aimed at optimising the
use of health records in research by facilitating the safe and
secure use, and linkage of, electronic patient records, re-
search data and routinely collected data [3].
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Using existing data in dementia research is not
unusual. Death certificates are often utilised to comple-
ment clinical follow-up methods where study partici-
pants are lost to follow up [4, 5]. Although studies have
used existing data for the purposes of dementia ascer-
tainment, to our knowledge no review has been pro-
duced in order to collate and consider the various
methods described. As a result, there is no clear guid-
ance or standard to follow when designing a study using
existing data for dementia ascertainment. The aim of
this systematic review is therefore to provide a narrative
account of the dementia ascertainment methods using
existing data sources described in the literature, in order
to provide evidence for potential approaches in future
research. It should be noted that this review focuses on
ascertainment from sources of existing data, rather than
on the specific dementia criteria utilised by each study.
This review is specifically aimed at providing a basis for
dementia ascertainment methods for studies based in
the UK, where there are highly developed systems allow-
ing the capture of health outcomes from a variety of
sources. This review will therefore not consider studies
based out-with the UK, as datasets vary widely between
countries and health systems. It is however likely that
some of the data sources considered in this review will
have an equivalent in other countries and so our conclu-
sions will have relevance outside the UK.
Methods
The Preferred Reporting of Items for Systematic Reviews
and Meta-Analyses (PRISMA) statement was used to
guide the conduct and reporting of the present system-
atic review [6].
Selection criteria
The ‘PICOS’ approach (population, intervention, com-
parator, outcome, study design) was adopted in order to
define the study question and build an appropriate
search strategy. Given that this review would focus on
methodology, the intervention and comparator were not
applicable. The population (P) would be a UK-based co-
hort or population group, the outcome (O) would be the
dementia ascertainment method and sources of existing
data, and the study design (S) would be observational.
This review aimed to guide future studies performing
dementia ascertainment using existing data within the
UK. This review will not consider populations out-with
the UK as health data and systems vary from that which
is available in the UK.
Data sources
Scholarly articles for inclusion in the review were identi-
fied through searching four separate electronic databases
determined to be appropriate for dementia ascertainment
methodology. The following databases were included:
MEDLINE (from 1946), EMBASE (from 1980),
PsychINFO (from 1987) and Web of Science (from
1900). The literature search took place on the 28th
December 2015.
Search strategy
The study authors (who have expertise in dementia) de-
veloped the search strategy with input from a research
librarian experienced in systematic review methodology.
Each search included terms relating to: a) dementia; b)
the UK; and c) longitudinal or cohort study type. The
full electronic search strategy for MEDLINE is detailed
in Additional file 1. No limitation parameters were used.
The inclusion and exclusion criteria for this review
aimed to strictly limit included papers to those using
previously collected data for dementia ascertainment.
Specifically, this required the exclusion of any paper
where dementia status was used to select participants or
where dementia was determined by prospective clinical
review. The exclusion criteria needed to be extensive
given the broad terms used for the initial literature
search. Such broad search terms were required given
that the area of interest was methodology, rather than
the primary topic of a study.
The inclusion criteria for review articles were: a)
Longitudinal or cohort studies applying retrospective de-
mentia ascertainment methods; b) Dementia cases must
be ascertained from a defined larger cohort/population;
c) Ascertainment may be an outcome, or ascertainment
may be performed in order to determine a cohort of par-
ticipants with dementia; d) Dementia diagnoses were
ascertained using existing data (in part or in full). Exist-
ing data included that which was collected routinely and
that which was collected for previous research.
The exclusion criteria were: a) Study population based
outside the United Kingdom; b) Articles published in
non-English language; c) Participant self-referral/other
referral to studies following advertising for persons with
dementia; d) Participant/carer/health service response to
census/survey; e) Participants included based on known
neuropathological diagnosis of dementia; f ) Direct refer-
ral of participants from NHS/voluntary services follow-
ing advertising/request for referral of persons with
dementia; g) Study participants recruited from hospital
wards, outpatient clinics (or referrals to the same) or
other services, unless documented that records/other
existing data used to select cases; h) Study participants
selected from an existing register of dementia cases,
study/research centre, memory or old age psychiatry
clinic patients, people prescribed cholinesterase inhibi-
tors or dementia carers; i) Studies where dementia was
not the primary condition or disease of interest, or at
least of equal weight to another condition; j) Animal
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models of dementia; k) Simulated cohorts; l) Ascertain-
ment not for dementia diagnosis (i.e. cognitive decline
‘suggestive of dementia’, cognitive impairment); m) Sys-
tematic reviews (any systematic review on this specific
topic would be included, but reviews producing sum-
mary data from several studies without any primary
description of dementia case ascertainment would be ex-
cluded) /meta-analyses/case reports – i.e. any non-
longitudinal or cohort study; n) Studies where dementia
cases were ascertained entirely at baseline and/or pro-
spectively in a clinical assessment setting; o) posters or
abstracts; p) unclear description, additional duplicates or
errors in citation.
Study selection
References were exported to and managed using the ref-
erence management software package Endnote X7.5.
The results from each database search were compiled
and any duplicates removed. Duplicates were identified
and removed by the ‘find duplicates’ function within the
Endnote software. Additional duplicates were then iden-
tified and removed manually. Records returned by the
literature search were excluded sequentially. In an initial
phase of screening, titles and abstracts were reviewed for
eligibility by the first author, according to the inclusion
and exclusion criteria. The threshold for inclusion at this
phase was purposefully low, to prevent the exclusion of
any relevant study. The full-texts of articles remaining
following the initial screening were obtained and inde-
pendently scrutinised by the first and second authors,
according to the same inclusion and exclusion criteria.
Any discrepancies between the final full-text lists for in-
clusion between the first and second authors were dis-
cussed and agreed upon at a meeting. It was planned
that any disagreements persisting following the meeting
would be discussed with a third author.
Where the list of eligible full-text articles included
more than one article by the same study group or au-
thor(s), and described the same ascertainment method-
ology, we included only the article with the most
comprehensive description of the methodology, and ex-
cluded all the others. This was done in order to prevent
bias in our findings. We aimed to prevent double-
counting of a single study which had given rise to mul-
tiple research outputs – where a single group or author
had published multiple articles using the same method-
ology from a single project. Including all such articles
would risk making it appear that a specific methodology
or data source was used more frequently and more
widely than in reality.
Data collection
The data extracted from the eligible full-text articles in-
cluded: the author(s), the journal reference (including
year of publication), the study topic or aim, whether de-
mentia ascertainment was the outcome or where it was
ascertained to form a cohort for further study, the
source(s) of existing data for dementia ascertainment,
the criteria for dementia ascertainment, and whether
there was any validation procedure or comparison with
expected dementia rates. Data were also extracted for
the purpose of evaluating the quality of the methodology
description, as detailed below.
Quality measure
A quality tool was developed by the authors in order to
evaluate the description of dementia ascertainment
methodology within each included article. The compo-
nents of the quality measure were based on whether the
paper contained sufficient information such that an inci-
dence or prevalence rate could be calculated and the as-
certainment rate could be compared with another
population. The components of the quality measure
considered the description of: a) the size of the baseline
population; b) the age of the baseline population; c) the
sex of the baseline population; d) the source of the base-
line population; e) the ascertainment procedure and f)
the date or time period studied. Each article was given a
quality score, with a higher score indicating a higher-
quality description of dementia ascertainment method-
ology. The maximum score was 16 and the full details of
the quality tool are shown in Table 1.
Where more than one eligible article reported results
based on the same study population and the same ascer-
tainment method, the article with the highest score for the
quality of description of dementia ascertainment method-
ology would be included and the others excluded from the
final review. These exclusions would be important in
order that studies or research groups with a high output
of articles from the same study, using the same ascertain-
ment methodology, did not bias the review findings. Spe-
cifically, we wanted to avoid certain methods appearing to
be frequently used within the UK when the same study
group was actually using them multiple times.
Results
Article selection
A total of 5031 citations were identified by the four separ-
ate database searches, including 2150 from MEDLINE,
1614 from EMBASE, 479 from PsychInfo and 788 from
Web of Science. After collating the search results, 1486
duplicates were removed. The title and abstract for each
of the remaining 3545 records was screened for suitability
and it was determined that 360 full-text articles required
full-text review. Of those selected for full-text review, it
was agreed that 63 articles met the criteria for inclusion.
A flow chart of study selection is shown in Fig. 1.
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The reasons for the exclusion of papers following full-
text review differed between the first and second au-
thors, largely since several papers could have been ex-
cluded for multiple reasons. Rather than excluding
articles based on multiple exclusion criteria the authors
made exclusions based on a primary exclusion criteria.
Despite the differences, both authors excluded the same
papers. The reasons for exclusion are therefore not de-
tailed in Fig. 1, but presented in Additional file 2: Table
S1. The most frequent reasons for the exclusion of full-
text articles (combined total number excluded by both
authors) were: cases ascertained entirely through base-
line or prospective clinical assessment or new data only
(n = 103), not a longitudinal or cohort study (n = 125)
and participants recruited directly from hospitals, clinics
or other service (n = 102). It would be expected that a
large number of ineligible or irrelevant articles were
returned by the literature search owing to the broad
search parameters used in order to identify a method-
ology rather than a specific study topic. Many such arti-
cles also passed through the first phase of screening
because the title and abstract did not contain sufficient
detail regarding the study methodology in order for eli-
gibility to be determined.
A number of the eligible articles reported results based
on the same study population and the same ascertain-
ment method was described multiple times. We identi-
fied nine groups of articles reporting the same
methodology and n = 16 articles were excluded on this
basis. Details of the excluded articles are shown
alongside the articles chosen for inclusion in Additional
file 3: Table S2.
Following this process, 47 papers remained for consid-
eration in this review. An overview of the characteristics
of the included studies can be seen in Table 2. The table
includes: the topic of the article; whether dementia as-
certainment was an outcome of the study or whether as-
certainment was performed to build a cohort of subjects
with dementia upon which further study was carried
out; whether existing data was used in full or in part; the
existing data sources utilised; the diagnostic criteria
used; whether the article included a validation study of
dementia ascertainment or a comparison between ob-
served rates and expected rates; and the total score
achieved when the quality tool was applied to each art-
icle. We determined that existing data was used in part
when new data was used in any way to support
Table 1 Quality Tool
Quality tool components
1 Baseline population size
A) Exact number (score = 3)
B) Approximate number (score = 2)
C) Other description of size (score = 1)
D) Not specified (score = 0)
2 Baseline population age
AI) Exact age range specified for total population (score = 4)
AII) Broad age range specified for total population (score = 3)
BI) Exact age range specified for analyses (score = 2)
BII) Broad age range specified for analyses (score = 1)
C) Not specified (score = 0)
3 Baseline population sex
A) Specified (score = 1)
B) Not specified (score = 0)
4 Baseline population
A) Named with description (score = 2)
B) Named only (score = 1)
C) Not specified (score = 0)
5 Dementia ascertainment
AI) Sources and specific criteria clearly described (score = 3)
AII) Sources and specific criteria less clearly described (score = 2)
B) Sources named but no specific criteria described (score = 1)
C) Unclear/ not described (score = 0)
6 Dementia cases
A) Number plus comparison to expected/ documented rate
(external UK comparison) (score = 2)
B) Number only (score = 1)
C) Not specified (score = 0)
7 Time/ period/ date
A) Specified
B) Not specified/ unclear
Fig. 1 Study Flow Design
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ascertainment. New data included clinical assessment,
informant interview and contact with services for
information.
Sources of data
The sources of existing data described by the eligible ar-
ticles were numerous and included general practice re-
search databases (n = 16), case notes or records
(n = 16), death certificates (n = 14), case registers
(n = 5), national datasets (n = 6), electronic hospital in-
formation systems (n = 2), radiology records (n = 3),
hospice records (n = 1), pharmacy records (n = 1) and
missing person records (n = 1). Of the 47 included pa-
pers, 31 (66%) used only a single source of existing data
for the purpose of ascertainment (Table 2). The highest
number of different data sources used was three. The
most commonly used data source in studies using a sin-
gle data source was a research database, such as the
General Practice Research Database (GPRD), the Clinical
Practice Research Datalink (CPRD), The Health Im-
provement Network (THIN) or the Scottish Programme
for Improving Clinical Effectiveness- Primary Care
(SPICE-PC) (n = 14). The next-most used data source in
articles using a single data source was death certificates
(n = 9). When considering all included papers, the re-
search database and case records or notes were equal as
the most frequently used sources (n = 16), but in those
papers using multiple sources only, case notes or records
were the most frequently utilised source of existing data
(n = 13). Figure 2 illustrates the source or sources of
existing data used by each of the 47 articles.
Of the 36 papers using existing data only for the pur-
pose of dementia ascertainment (i.e. no clinical compo-
nent), 27 (75%) used only a single data source and the
most frequently utilised data source was the research data-
base (n = 14). Including the articles that only used existing
data and used single or multiple sources, the research
database remained the most frequently used (n = 16), but
considering those using multiple sources separately, case
notes were the most frequently used (n = 6).
The criteria utilised by the articles to determine a
diagnosis of dementia from the data sources was varied.
Most studies using death certificates for dementia ascer-
tainment extracted a diagnosis based on the condition
having been recorded on any part of the certificate.
Others stated that dementia cases were recognised by
specific ICD-10 codes listed on the certificate. Evidence
from death certificates were also used in combination
with evidence from other sources to determine cases.
Case records were in many cases reported to be exam-
ined by a specialist medical doctor with training in de-
mentia. Researchers often searched the case records for
evidence to meet a specific diagnostic criteria, such as
DSM-IV, ICD-10 or NINCDS-ADRDA criteria. In other
cases, dementia diagnosis was taken as a formal diagno-
sis or mention of a diagnosis within in the notes. Re-
searchers employed a number of different techniques
when using databases to ascertain dementia diagnoses.
These included searching the database for diagnostic
codes, Read Codes derived from Quality and Outcomes
Framework (QOF) codes, recorded diagnoses or pre-
scriptions for dementia defining drugs. Some studies ap-
plied diagnostic criteria to evidence within the records.
Other studies developed algorithms that combined a
number of different criteria. Details of the criteria uti-
lised by each study is shown in Table 2.
Quality measure
The quality measure was primarily a means of evaluating
the description of the ascertainment methodology and
the sources of data used. We identified significant dis-
crepancies between the detail provided in the method-
ology of articles and the quality measure results give an
indication of the completeness or lack of information
provided by the authors. The quality measure is there-
fore closely related to our reporting of the sources used
and how dementia was ascertained from each.
The breakdown of the quality measure results for each
article are shown in Additional file 4: Table S3. When an
article included sub-studies where dementia was included
as an outcome in one study and for a dementia cohort
study in another, the quality measure was performed on
the outcome study due to the more specific detail in-
cluded. Where only one sub-study met the inclusion cri-
teria for this review, the results listed considered only the
eligible sub-study. Overall, the quality scores ranged from
7/16 [7, 8] to 16/16 [9, 10] and the mean score achieved
across all 47 papers was 12.0 (SD: 2.6). Quality scores were
lower for studies using existing data alone for ascertain-
ment (n = 36; mean = 11.5 (SD 2.6)), compared with stud-
ies using existing data in addition to other methodologies
(n = 11; mean 13.4 (SD 2.3)) (p < 0.05). There was also a
significant difference (p < 0.001) in quality scores between
studies where dementia was either an outcome or both an
outcome and the basis of forming a cohort (n = 31;
mean = 13.0 (SD 2.1)), and studies where dementia ascer-
tainment was performed to build a cohort (n = 16;
mean = 10.2 (SD 2.6)).
The quality measure also included whether a valid-
ation study or comparison with expected dementia rate
was performed. Given the importance of validating an
ascertainment methodology in order to determine its ef-
fectiveness we have expanded on this further, as follows.
Studies reporting a validation procedure
Of the 47 papers included, relatively few performed a valid-
ation study for dementia cases or compared ascertainment
Sibbett et al. BMC Psychiatry  (2017) 17:239 Page 9 of 16
to previously documented rates. Imfeld et al. [11] com-
pleted a validation procedure for the algorithm used to
identify cases within the General Practice Research Data-
base (GPRD), and found up to 80% of Alzheimer’s disease
cases and up to 75% of vascular dementia cases were con-
firmed by GP questionnaire responses. Seshadri et al. [12]
completed a validation of Alzheimer’s disease cases identi-
fied using code algorithms for dementia or Alzheimer’s dis-
ease within GPRD and confirmed only 48% cases as either
possible or probable Alzheimer’s disease according to
NINCDS-ADRDA criteria. Authors did however report a
much higher validation rate of 83% for those identified spe-
cifically as Alzheimer’s disease cases within the GPRD, and
for whom there was adequate data for validation [12].
Imfeld et al. [11] reported that the incidence rates of Alz-
heimer’s disease found in their study, were three to six
times lower than those found in previous European studies.
Goh et al. [13] and Qizilbash et al. [14] did not perform any
validation study, but referred to the above-mentioned work
by Seshadri et al. [12, 15]. Using the Scottish Programme
for Improving Clinical Effectiveness- Primary Care (SPICE-
PC) database, Guthrie et al. [16] found that the prevalence
of dementia was only about half of that found in epidemio-
logical studies. Recording was found to be particularly poor
in older age groups. Rait et al. [17] used The Health Im-
provement Network (THIN) database and on comparison
with incidence rates demonstrated by the EURODEM study
and Cognitive Function and Ageing Study (CFAS), the inci-
dence rates found by Rait et al. were shown to be signifi-
cantly lower than would have been expected [17]. Heath et
al. [9], who did not name the research database used, re-
ported the prevalence in their population to be close to the
middle of the range of previous estimates.
The under-reporting of dementia on death certificates
was noted in articles in this review [10, 18–20]. Doll et
al. [21] compared their findings to European statistics
(EURODEM) and determined that they had only re-
corded 30% of dementia cases from death certificates.
Russ et al. [10] found that compared to using multiple
sources, death certification alone missed approximately
16–18% of dementia cases. The same study found that
general practice records did not identify all cases identi-
fied by record linkage [10].
McGonigal et al. [22] tested the assumption that most
patients with pre-senile Alzheimer’s disease are known
to psychiatric services. After consulting further data
sources including death certificates, general hospital and
neurology service records, and opinions within the med-
ical community, the authors reported that approximately
97% of participants identified as having pre-senile de-
mentia in their study were indeed cared for within psy-
chiatric services [22]. Overall, McGonigal et al. [22]
found that the annual incidence rates of pre-senile Alz-
heimer’s disease, determined using hospital records,
within their study population were comparable to annual
incidence rates quoted by a national study using differ-
ent ascertainment methods. It should be noted that
some 11% of hospital records requested by McGonigal
et al. [22] were either lost or contained insufficient data
to apply the diagnostic criteria. If the proportion of
probable dementia in missing records was the same as
for the available records, 12% of cases would have been
missed as a result [22]. Crugel et al. [7] did not perform
any validation study but did note that it was known that
the number of dementia cases identified using their elec-
tronic record system was lower than the number known
to the hospital trust. Renvoize et al. [23], who used local
computerised medical and social records for case identi-
fication, found a prevalence rate consistent with previous
studies. Pendlebury et al. [5] state an awareness of
Fig. 2 Sources of Existing Data for all Included Articles
Sibbett et al. BMC Psychiatry  (2017) 17:239 Page 10 of 16
under-recording of dementia diagnoses in primary care
records and Sampson et al. [24] report that dementia is
under-diagnosed in the acute hospital setting. Shah et al.
[25] also acknowledge the deficiencies in recognition
and recording in primary care, and note that the preva-
lence found in their study is lower than what might be
expected, based on epidemiological surveys. Newens et
al. [26] used hospital information systems and clinical
records to ascertain the incidence and prevalence of
early onset dementia. The authors reported a similar
prevalence rate to rates documented elsewhere.
Ryan [27] acknowledged potential diagnostic and cler-
ical errors within the Scottish Morbidity Records (SMR)
from Information Services Division (ISD) Scotland. A
validity rate of 84% is quoted from a previous work by
the same author [27]. Russ et al. [10] also note the
likelihood that SMR datasets will miss some cases of de-
mentia. Stephens et al. [28] highlight the possibility of
under-recording in Hospital Episode Statistics (HES),
particularly those with earlier or milder forms of demen-
tia. Keenan et al. [29] question the reliability of dementia
subtype diagnoses within HES. Those studies describing
a validation study or making a comparison with
expected rates are shown alongside their respective
methodologies in Additional file 5: Table S4.
Brayne et al. [30], Brayne et al. [31] and Clarke et al.
[4] made comparisons of prevalence with expected or
previously documented rates. As these studies used
existing data in part only, it is not possible to draw con-
clusions regarding the sources of existing data that were
used based on these comparisons.
Discussion
Our systematic review identified 47 articles relevant for
inclusion. 36 articles used existing data sources alone for
dementia ascertainment, whilst 11 used existing data in
conjunction with new data. The existing data sources
utilised by the 47 articles included: research databases,
death records, clinical notes, national datasets, hospital
information systems, radiology records, missing person
records, pharmacy records and hospice records. The
most commonly used sources were research databases,
clinical records and death records. The quality of the de-
scription of dementia ascertainment methodology varied
widely, with scores from 7 to 16 out of a maximum
score of 16. Most studies that completed a validation
procedure for dementia ascertainment found that
observed rates of dementia were lower than expected.
The initial literature search returned a substantial
number of articles in comparison to the number that
were included for final analysis. As this review consid-
ered a methodology rather than an outcome or specific
dementia-related topic, it was necessary to write a broad
and inclusive search strategy so as not to miss any
relevant articles. As such, it was anticipated that a high
proportion of articles would be excluded. The articles in-
cluded in the final analysis covered a wide variety of spe-
cific study topics. The results of the quality measure
varied widely, but those papers demonstrating the poor-
est scores for quality of description were, in nearly all
cases, papers in which dementia ascertainment was per-
formed in order to build a cohort for further study [7, 8,
19, 32–34]. This might be expected given that dementia
ascertainment was not the focus of these studies and
thus the descriptions of method concentrated on other
aspects of the studies.
Our assessment of methodology is primarily a narra-
tive account of the sources of existing data utilised in
the included articles. The purpose of this review does
not include repeating previous extensive literature that
compares and comments on diagnostic criteria. The aim
is to outline each source and provide some evidence re-
garding the usefulness or drawbacks of the source.
All of the research databases used by papers in this re-
view rely on the collection of anonymised patient data
contributed by participating general practices within the
UK. Databases such as the Clinical Practice Research
Database (CPRD) have been designed in order to facili-
tate data-linkage across services, including Hospital Epi-
sode Statistics [32]. General practice databases have
been used widely in medical research and it has been re-
ported that usage of the General Practice Research Data-
base (GPRD) and Clinical Practice Research Database
have resulted in over 800 and 1500 publications respect-
ively [35, 36]. Each database collects data from several
hundred general practices and provides records for mil-
lions of patients [13, 35, 37]. The volume of data avail-
able and the number of general practices involved in
such databases indicate a clear benefit to the use of these
resources. In order to determine the usefulness of gen-
eral practice research databases, we must ascertain the
validity of diagnostic coding for dementia within the da-
tabases. We might consider this in two ways: firstly, do
diagnoses contained within the database correlate with
information within the general practice records; and sec-
ondly, are dementia cases recorded within general prac-
tice records an accurate reflection of dementia rates
within the population? Using GP questionnaires, Dunn
et al. [38] completed a validation study of dementia cases
and controls drawn from the GPRD and reported a con-
firmed diagnosis in 83% of recorded cases. This rate is
similar to those reported for Alzheimer’s disease by
studies in this review: Imfeld et al. (80%) [11] and
Seshadri et al. (83%) [12]. Seshadri et al. did, however,
find a much lower validation rate when considering both
dementia and Alzheimer’s disease together (48%) [12].
Dunn et al. [38] did not consider dementia prevalence in
the study population against previously reported national
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statistics or alternative databases. In this review, Imfeld
et al. [11], Guthrie et al. [16], and Rait et al. [17] all re-
ported lower than expected ascertainment rates from
the GPRD, SPICE-PC and THIN database respectively,
when compared to previously documented incidence
and prevalence. From the findings of the articles in-
cluded in this review, we would suggest that dementia
diagnoses within a general practice research database are
not a completely accurate reflection of dementia cases
known to the GP or within a population.
A distinct advantage of using death certificates for de-
mentia ascertainment is their availability and the ease of
data collection from this source. As dementia is not al-
ways the primary cause of death, the inclusion of the
diagnosis on the death certificate relies on both the
certifying doctor’s familiarity with the patient’s medical
history and their opinion as to whether the diagnosis
merits inclusion on the certificate. Despite the import-
ance of dementia as a contributory factor or cause of
death, rates of reporting on death certificates have
historically been poor [39, 40]. A more recent Scottish
study did however illustrate an improvement, with
71.5% of deceased patients from a group with known de-
mentia having the diagnosis correctly recorded on their
death certificate [41]. In this review, both Doll et al. [42]
and Russ et al. [10] demonstrated such under-reporting.
It is clear that, despite improvements in diagnosis and
reporting, we cannot rely on death certificates to give a
completely accurate reflection of dementia cases within
a population and studies using this source alone are fail-
ing to achieve the best possible ascertainment rates.
The national datasets used by studies in this review in-
clude Scottish Morbidity Records (SMR) from the Infor-
mation Service Division (ISD) of NHS National Services
Scotland and Hospital Episode Statistics (HES). SMR are
sets of permanently linked datasets, and specifically,
SMR01 is a record of inpatient and day-case general hos-
pital admissions, whilst SMR04 is a record of inpatient
and day-case psychiatric admissions [43]. HES is a na-
tional dataset containing records of all admissions, out-
patient appointments and A&E attendances at NHS
hospitals in England [44]. In this review, Stephens et al.
[28] and Keenan et al. [29] highlight the likelihood of
under-recording or inaccuracies in the HES data, but a
recent study found that when compared with dementia
recording in CPRD and General Practitioner survey re-
sponses, HES was accurate in 85% of cases [45]. In order
to make assurances regarding the quality of published sta-
tistics, ISD Scotland complete regular assessments of col-
lected data. The report published in 2015 found an 89%
accuracy for the main diagnosis and a 77.5% accuracy for
dementia diagnoses in SMR01 [46]. In our review, Ryan
[27] reports a validity rate of 84% based on a previous
work. Out-with this review, Russ et al. [47] found that
while SMR01 only recorded 53% of known cases of de-
mentia, SMR04 recorded dementia 100% of the time in a
cohort of people with known dementia. This would sug-
gest that where a diagnosis of dementia has been made in
a psychiatric unit, it is reliably reported within the national
dataset SMR04. As most health assessment and treatment
in the UK takes place within the National Health Service
(NHS) it can be assumed that these datasets are represen-
tative of the whole population. They can also be used for
large-scale studies. The main drawbacks of these datasets
would be that any cases not seen in hospital services
would be missed, they rely on cases having been diag-
nosed, the cases having been diagnosed correctly, and they
rely on the diagnoses being recorded in the relevant rec-
ord systems.
The findings of the study by McGonigal et al. [22]
would suggest that psychiatric records and psychiatric
case registers are valuable and accurate data sources for
pre-senile dementia case ascertainment. It should how-
ever be noted that these are historical data, mostly over
30 years old, and admission policies for psychiatric
hospitals in Scotland and the UK have changed over that
period so this assumption may no longer be tenable. It is
possible that a diagnosis, although recorded within clin-
ical records, is simply incorrect. A 2012 Danish study
highlighted this issue and in a study of 195 patients reg-
istered as having a diagnosis of early onset dementia, the
authors found that the diagnosis was correct (according
to DSM-IV or ICD-10 criteria) in just 58% of cases [48].
It would therefore seem reasonable to suggest that the
most reliable diagnosis taken from written data sources
will be where the evidence for diagnostic criteria is
present as well as the diagnosis itself.
Studies aiming to evaluate the quality of source infor-
mation might compare the data collected with informa-
tion from a second source, for example paper medical
records [49]. Concordance between two sources in-
creases the likelihood of correctness, and completeness,
but it should be recognised that no source can be as-
sumed to be completely accurate – there is no true
“gold-standard” [49]. A diagnosis present in more than
one source may superficially appear to be reliable; how-
ever, we must consider the possibility that a diagnosis of
dementia was initially entered into the notes in error
and simply transcribed from one record to another. Be-
tween October 2014 and September 2015, the National
Patient Safety Agency received almost 99,057 reports re-
lating to failures in documentation from NHS organisa-
tions in England and Wales [50].
In using previously collected data for dementia case
ascertainment, we are relying on diagnoses having been
made and recorded. Using existing data is therefore most
effective when diagnostic rates are high. Any population
with a poor record for detecting dementia might yield
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different study results, particularly if undiagnosed cases
are associated with particular factors or variables. Regional
variation in rates of diagnosis have been reported previ-
ously, suggesting that the use of existing data might be
more reliable in some geographical areas [51, 52].
All of the sources described by studies included in this re-
view have value, and all are likely to provide ascertainment
data for a majority of cases within a population. It would be
prudent, however, to be cautious in accepting any docu-
mented case as correct without evidence to substantiate the
diagnosis. Similarly, if a single source is used, the possibility
of missing cases should be considered. We must establish
methods for minimising any error, but one should be realis-
tic and accept that any dementia ascertainment method will
be open to some error. The main drawback to using exist-
ing data of any kind is the potential for undiagnosed cases
being missed. For this reason, the most accurate dementia
ascertainment process is likely to include prospective
follow-up with clinical assessment. Using such methods
does however have its own limitations. Collecting prospect-
ive data in an ageing population is time-consuming and can
lead to delays in the release of findings. This is particularly
true if we are to consider influences across the life course
or premorbid risk factors. Prospective studies are subject to
attrition, due to death or other causes. Using clinical
follow-up also restricts the size of a study cohort, with finite
funding and resources available for each study. Also signifi-
cant is the variability of clinical assessment methods across
studies, making the comparison of study results less accur-
ate. Within the UK there is an ongoing drive to improve
rates of dementia diagnosis and, as such improvements are
made, existing data will become increasingly accurate and
their use for dementia ascertainment will become increas-
ingly valuable in the study of dementia.
Considerations for future studies
The evidence for the accuracy of the sources discussed may
not be comprehensive and conclusive, but we must attempt
to make suggestions for a ‘best possible’ method when per-
forming dementia ascertainment using existing data. In
order to minimise any missed cases it would be sensible to
collect data from multiple data sources. This might elimin-
ate those cases that have simply failed to be recorded des-
pite a diagnosis having been made. In accessing multiple
sources, we may also be more confident that those without
a recorded diagnosis are truly dementia free. The most use-
ful method for determining whether any diagnoses are cor-
rect would be to consider evidence for a diagnosis within
the existing data. Evidence consistent with diagnostic cri-
teria for dementia may not only confirm recorded cases,
but identify cases that have failed to be recorded.
When deciding which combination of sources to in-
clude in an ascertainment methodology it is useful to
consider the advantages and disadvantages of each
source, and which combination of sources are likely to
yield the highest number of cases. Diagnoses derived
from hospital records are of particular value given the
high rates of hospital admission for persons with demen-
tia. [53] At a given time-point, it has been estimated that
6% of inpatients in a general hospital have dementia,
while 0.6% are aged over 65 and without dementia. [53]
National datasets derived from hospital records (such as
Hospital Episode Statistics) should contain the same
diagnoses as the hospital records themselves. It is how-
ever possible that in some situations, such as when there
is increased demand on a service, only the main diagno-
sis is coded. Although the list of diagnoses might be the
same, the records could contain further detail to allow
for confirmation of the diagnoses. In this sense they may
be considered more accurate. The nature of datasets
mean that a list of diagnoses, or list of participants with
a particular diagnosis can however be made available for
a much larger population and in a more time efficient
manner. Both, therefore, have their advantages and dis-
advantages, but using both is unlikely to yield many add-
itional cases. The choice of which to use of the two
would depend on the requirements of the study. The
similarities, advantages and disadvantages between GP
records and GP research databases would be much the
same as those described for hospital records. The benefit
of GP records over hospital records are that they are
more likely to contact records from external services
such as social work and housing and contact is likely to
be more frequent. These benefits might increase the
chance of a diagnosis or symptoms having been re-
corded. Death certificates have the advantage of being
readily available and they are particularly useful as
follow-up for participants who do not provide consent
for access to records or data linkage. For these reasons,
death records would be a useful addition to any other
source being used for ascertainment. The disadvantages
are that they rely on the physician deeming the diagnosis
significant enough to warrant inclusion on the death cer-
tificate and they are of no use in identifying dementia
cases in the living. Death records and national datasets
have the advantage of not being restricted to a specific
locality or area, compared with electronic health records
that might be held on a different system in each health
board. The recording of dementia diagnoses within these
sources depends on the proportion of dementia cases
identified in the community- in the UK this has previ-
ously been shown to be less than 50%. [54].
All of the sources described are likely to identify de-
mentia cases at the more severe end of the spectrum.
Regardless of the source, the diagnosis of dementia is
more likely to have been made if the condition is more
severe and it is therefore more likely to have been re-
corded. In contrast, early cases are more likely to remain
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undiagnosed and, as such, would not appear in any
existing data. In the case of hospital or GP records or
databases, the more severe the condition, the more likely
they are to have had contact with a healthcare provider.
Similarly, the higher the number of co-morbidities, the
more likely they are to have contact with services. This
regular contact with services for management of comor-
bidities may also mean that a diagnosis is more likely to
have been made. The more severe the dementia, the
more likely it is to be considered a significant factor in
cause of death and it is therefore more likely to be re-
corded on a death certificate.
Clinical assessment is probably the best method for
identifying early cases of dementia. There are however
problems with non-random screening participation. [55]
Early cases are more likely to be recorded in existing
data if cases are being identified and diagnosed at an
early stage within the community. Diagnoses are in turn
more likely to be made if the physician is aware of the
condition, appreciates the benefits of diagnosis and is
confident in making a diagnosis, or referring for a spe-
cialist opinion. Investments in research and public health
raise the awareness of dementia among physician, and
the general population, meaning that patients are en-
couraged to present to services rather than accept that
changes are merely a consequence of ageing.
Limitations of the review
Given the variability in the quality of the description of
methodology for dementia ascertainment and, in par-
ticular, the number that did not provide sufficient infor-
mation such that an incidence or prevalence rate for
dementia could be derived, it was not possible to draw
comparisons between the ascertainment rates for differ-
ent methodologies. A future study considering dementia
ascertainment methodologies, using existing data, in in-
cidence and prevalence papers only, might provide the
opportunity for direct comparison and an assessment of
the effectiveness of different methodologies. It would
also be worthwhile for such a study to include studies
based out-with the UK. As our study did not, we may
have missed ascertainment methodologies that could be
replicated using UK sources of existing data. With the
use of existing data in dementia studies continuing, it
may be worthwhile to consider updating this review in
due course. Given that, a single author performed phase
one screening of titles and abstracts there is the poten-
tial for error. This is, however, unlikely given that the
broad search strategy returned a large number of articles
that were obviously not relevant to the review.
Conclusions
In conclusion, our review revealed a lack of consistency
with regard to dementia ascertainment methodology
using existing data in previous UK studies. Optimising
ascertainment is of essential importance in order to in-
crease statistical power, avoid selection bias and enable
comparability between studies. We described the bene-
fits of a number of sources of existing data including:
death records, national datasets, research databases, and
hospital records. Evidence suggested that although each
was useful, none was completely accurate when used
alone and we would therefore recommend that future
studies use a combination of these data sources. Where
possible, studies should access records with evidence to
confirm, query, or refute the diagnosis. Studies should
also calculate a dementia ascertainment rate for the
study population to allow for comparison to an expected
or previously documented rate. Not only would this help
in judging the findings of an individual article, but it
would also provide further evidence for guiding demen-
tia ascertainment methodology using existing data.
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